Abeona Therapeutics (NASDAQ:ABEO) CEO Sells $131,000.00 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Vishwas Seshadri sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $5.24, for a total value of $131,000.00. Following the completion of the sale, the chief executive officer directly owned 1,190,067 shares in the company, valued at approximately $6,235,951.08. This trade represents a 2.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Vishwas Seshadri also recently made the following trade(s):

• On Monday, September 29th, Vishwas Seshadri sold 19,274 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.39, for a total value of $103,886.86.
• On Wednesday, July 9th, Vishwas Seshadri sold 69,420 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.86, for a total value of $406,801.20.

Abeona Therapeutics Stock Performance

ABEO stock opened at $5.32 on Friday. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The stock has a market capitalization of $272.81 million, a price-to-earnings ratio of 7.60 and a beta of 1.42. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.65 and a current ratio of 6.73. The stock’s fifty day moving average is $6.38 and its two-hundred day moving average is $5.92.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $21.71 million. On average, research analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on ABEO. Oppenheimer raised their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, August 18th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $19.50.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Boone Capital Management LLC acquired a new position in shares of Abeona Therapeutics in the 2nd quarter worth approximately $7,126,000. Geode Capital Management LLC boosted its holdings in Abeona Therapeutics by 129.1% during the second quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after buying an additional 623,243 shares in the last quarter. JPMorgan Chase & Co. grew its position in Abeona Therapeutics by 255.6% in the second quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after buying an additional 597,373 shares during the last quarter. Nan Fung Trinity HK Ltd. bought a new position in shares of Abeona Therapeutics in the second quarter valued at $3,185,000. Finally, AWM Investment Company Inc. acquired a new stake in shares of Abeona Therapeutics during the 2nd quarter valued at $2,670,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.